Edition:
United Kingdom

CytRx Corp (CYTR.OQ)

CYTR.OQ on NASDAQ Stock Exchange Capital Market

0.53USD
12 Dec 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.53
Open
$0.52
Day's High
$0.55
Day's Low
$0.50
Volume
20,642
Avg. Vol
20,235
52-wk High
$2.35
52-wk Low
$0.50

Latest Key Developments (Source: Significant Developments)

Cytrx Announces $7.0 Million Registered Direct Offering
Friday, 11 May 2018 

CytRx Corp ::CYTRX ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING.CYTRX - ENTERED PURCHASE AGREEMENTS WITH CERTAIN INSTITUTIONAL INVESTORS TO SELL IN REGISTERED DIRECT OFFERING 5.6 MILLION SHARES AT PRICE OF $1.25/SHARE.  Full Article

Cytrx Reports First Quarter Loss Of $0.15 Per Share
Tuesday, 8 May 2018 

May 8 (Reuters) - CytRx Corp ::CYTRX REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.15.CASH AND CASH EQUIVALENTS OF $35.1 MILLION AS OF MARCH 31, 2018.  Full Article

Cytrx reports strategic realignment of clinical development team
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Cytrx Corp ::Cytrx announces strategic realignment of clinical development team.Cytrx - announced ‍strategic realignment of drug development efforts for advancing new drug candidates based on ladr technology platform​.Cytrx Corp - co's drug development, manufacturing and regulatory activities will be led by Hurley Consulting Associates​.Cytrx Corp - ‍is poised to file INDS with FDA for one or more new ladr drug conjugates in 2018​.  Full Article

Cytrx Corp announces reverse stock split
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Cytrx Corp :Cytrx Corporation announces reverse stock split.Cytrx Corp- ‍1-for-6 reverse​ stock split will become effective as of commencement of trading on Wednesday, November 1, 2017.  Full Article

Cytrx corp says ‍Nasdaq has granted co's request for a continued listing
Tuesday, 17 Oct 2017 

Oct 16 (Reuters) - Cytrx Corp ::Cytrx corp - ‍Nasdaq has granted co's request for a continued listing pending results of a stockholder vote on or before October 30, 2017​.  Full Article

Cytrx highlights inclusion of aldoxorubicin in pending upcoming clinical trial submissions
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Cytrx Corp ::Cytrx Corporation highlights inclusion of aldoxorubicin in pending upcoming clinical trial submissions planned by Licensee Nantcell, Inc..  Full Article